

C[MV] You Later: Letermovir for Prevention of Cytomegalovirus Infection

ACPE Universal Activity Number (UAN):

JA0000238-0000-20-028-L01-P

Session Date: 06/09/2020

Session Time: 11:00 – 11:45 AM (CST)

Session Type: Knowledge-based

Session Fee: Free for Mayo Clinic staff

CE Credit Types: A maximum of 0.75 contact hour (0.075 CEU) for the following:

- AAPA Category 1 CME Credits
- ACPE
- *AMA PRA Category 1 Credits™*
- ANCC

Target Audience

This continuing education (CE) session was planned to meet the needs of professional staff who deal with the selection and monitoring of medication(s) as part of their patient care duties, including: pharmacists, RNs, APRNs, PAs, MDs.

Activity Overview

Cytomegalovirus (CMV) is an opportunistic infection that occurs frequently in hematopoietic stem cell transplant (HSCT) recipients, causing significant morbidity and mortality. Traditionally, ganciclovir and valganciclovir have been utilized for CMV prophylaxis and treatment; however, their myelosuppressive properties become problematic in patients following HSCT. Letermovir, a new antiviral agent that does not share these myelosuppressive effects, was approved in 2017 for CMV prophylaxis in HSCT recipients. In this presentation, I will review the literature supporting use of letermovir for CMV prophylaxis in HSCT, identify patients who would benefit from a letermovir-based prophylaxis strategy, and discuss investigational uses for this agent.

Learning Objectives

At the conclusion of this knowledge-based CE session, participants should be able to:

1. Explain the difference between pre-emptive and prophylaxis strategies for cytomegalovirus infection prevention
2. Select patients that may benefit from letermovir prophylaxis based on existing literature
3. Identify areas of investigational use of letermovir

Faculty Information

Mikhaila L. Rice, PharmD

PGY1 Pharmacy Resident

Mayo Clinic Hospital - Rochester, MN

Mikhaila received a Doctor of Pharmacy degree from the University of Pittsburgh School of Pharmacy in Pittsburgh, PA. She is a current PGY1 Pharmacy Resident at Mayo Clinic Hospital-Rochester with practice interests in hematology, oncology, immunology, and infectious disease.



Approved Provider Statement



JOINT ACCREDITATION™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity is planned and implemented by Mayo Clinic College of Medicine and Science. Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Statements

AMA

Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 0.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACPE

Mayo Clinic College of Medicine and Science designates this educational activity for a maximum of 0.75 ACPE Knowledge-based contact hours. Participants should claim only the credit commensurate with the extent of their participation in the activity.

ANCC

Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 0.75 ANCC nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

AAPA



Mayo Clinic College of Medicine and Science has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Educational Format and CE Requirements

This CE session is available as a live presentation, including live webcast.

Participants must complete the following to record attendance and obtain CE credit:

1. Attend the entire session.
2. Text the session code to 507-200-3010 within 48 hours of the live presentation to record attendance.
 - a. This number is only used for receiving text messages related to tracking attendance
 - b. Employees are encouraged to create a contact in their mobile phone, as the same number is used to record attendance for every session
3. Complete the online evaluation for the respective session within 2 weeks of live presentation.

Pharmacist CE credit is electronically transferred to the National Association of Boards of Pharmacy CPE Monitor. To track CE, please go to [NABP CPE Monitor](#).

Non-pharmacist attendees can print out a record of attendance at ce.mayo.edu after completing the evaluation and claiming credit.

[Live Webcast](#) - access during presentation times

[Video Recording](#) - access two weeks after session date

Disclosure Statement

As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

- Mikhaila L. Rice, PharmD
 - Declares no financial relationship(s) pertinent to this session
 - Declares off-label use of devices and medications will be discussed during this presentation, including:
 - Letermovir

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session. Members include:

- | | |
|---|-------------------------------------|
| • Brenda Amaris | • Wayne Nicholson, MD, PharmD, BCPS |
| • Mary Ellen Cordes, MS, APRN, CNS, NE-BC | • Garrett Schramm, PharmD, BCPS |
| • Michael Huckabee, MPAS, PA-C, PhD | • Lee Skrupky, PharmD, BCPS |

For additional disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee members visit ce.mayo.edu, About Us, Disclosures - or -

<https://ce.mayo.edu/content/disclosures>

System and Technical Requirements

For participants viewing the webcast, sessions are delivered via Mayo Clinic intranet web browser and Adobe® PDF. For participants viewing outside the Mayo Clinic firewall, a VPN connection is required for remote access. Recommended web browsers include: Google Chrome, Firefox, Internet Explorer 10 or 11.

This session is planned and coordinated by **the Department of Pharmacy, Mayo Clinic.**